January 7, 2015 | An Israeli biopharmaceutical company, cCAM Biotherapeutics, announced that it received Food & Drug Administration approval to begin a Phase I trial for CM-24. CM-24 is a antibody for the treatment of various types of cancers. cCAM was founded in 2010 and focuses on the discovery and development of novel immunotherapies to treat cancer. The CM-24 antibody was discovered by Dr. Gal Markel, Head of Research in the Ella Institute of Melanoma at Sheba Academic Medical Center.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments